ClinicalTrials.gg
CompletedNCT02343458Updated Feb 20, 2019Results posted

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

A Phase 3 interventional study of GFF MDI (PT003) and FF MDI (PT005) in Chronic Obstructive Pulmonary Disease, sponsored by Pearl Therapeutics, Inc.. Completed at 167 sites in 11 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-02-20.

Sponsored by Pearl Therapeutics, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,756
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
6th of 73
1,756 · median 152
Started
2015
with 7 others
Phase 3
33 of 73
1 open now
Registered
44th of 73
by date
Lead sponsor
18 of 73
Pearl Therapeutics, Inc.

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 6th largest by enrollment, is one of 8 that started in 2015, is one of 33 in phase 3, and was the 44th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

A chronic dosing (24 weeks) study to assess the efficacy and safety GFF MDI; PT003), FF MDI; PT005, and GP MDI; PT001) in subjects with moderate to very severe COPD, compared with placebo.

Read the detailed description

A randomized, double-blind, chronic dosing (24 weeks), placebo-controlled, parallel group, multi-center study to assess the efficacy and safety of glycopyrronium and formoterol fumarate inhalation aerosol (GFF; PT003), formoterol fumarate inhalation aerosol (FF; PT005), and glycopyrronium inhalation aerosol (GP; PT001) in subjects with moderate to very severe COPD, compared with placebo.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • COPD
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-child bearing potential (ie, physiologically incapable of becoming pregnant, including any female who is 2 years ); or Child bearing potential, has a negative serum pregnancy test at Visit 1, and agrees to acceptable methods used consistently and correctly for the duration of the study.
  • Subjects with an established clinical history of as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS).
  • Current or former smokers with a history of at least 10 pack-years of cigarette smoking.
  • /forced vital capacity (FEV1/FVC) ratio of \<0.70.
  • FEV1 must be \<80% predicted normal value calculated using the Third National Health and Nutrition Examination Survey (NHANES III) reference equations. (Or reference norms applicable to other regions).

Exclusion criteria

Exclusion Criteria:

  • Significant diseases other than , ie, disease or condition which, in the opinion of the Investigator, may put the subject at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study.
  • Women who are pregnant or lactating or women of who are not using an acceptable method of .
  • Subjects, who in the opinion of the Investigator, have a current diagnosis of asthma.
  • Subjects who have been hospitalized due to poorly controlled COPD within 3 months prior to Visit 1 (Screening) or during the Screening Period (Visit 1 to Visit 4).
  • Subjects who have poorly controlled COPD, defined as acute worsening of COPD that requires treatment with oral or antibiotics within 6 weeks prior to Visit 1 (Screening) or during the Screening Period (Visit 1 to Visit 4).
  • Subjects with a diagnosis of angle closure glaucoma will be excluded, regardless of whether or not they have been treated. Subjects with a diagnosis of open angle glaucoma who have intraocular pressure controlled with medication(s) are eligible.
  • Subjects who have a history of to β2-agonists, glycopyrronium or other muscarinic anticholinergics, or any component of the MDI.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,756 participants (actual)

Study arms

  • Experimental
    GFF MDI (PT003)

    Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)

    Drug: GFF MDI (PT003)

  • Experimental
    FF MDI (PT005)

    Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)

    Drug: FF MDI (PT005)

  • Experimental
    GP MDI (PT001)

    Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)

    Drug: GP MDI (PT001)

  • Placebo comparator
    Placebo MDI

    Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)

    Drug: Placebo MDI

Interventions

  • DrugGFF MDI (PT003)

    Drug pages: Glycopyrrolate · Formoterol

    Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)

    Also known as: Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol

  • DrugFF MDI (PT005)

    Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)

    Also known as: Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol

  • Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)

    Also known as: Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol

  • DrugPlacebo MDI

    Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)

    Also known as: Placebo (matching) for GFF MDI, FF MDI, and GP MDI

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 of Treatment (US/China Approach)

    For the US/China approach, the primary endpoint was the change from baseline in morning pre-dose trough FEV1 at Week 24 of treatment

    Time frame: at week 24

  2. Change From Baseline in Morning Pre-dose Trough FEV1 Over Weeks 12-24, Japan Approach

    Change from baseline in morning pre-dose trough FEV1 over weeks 12-24, Japan approach

    Time frame: over weeks 12-24

  3. Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks. Primary Endpoint, EU/SK/TW Approach, Secondary Endpoint US/China Approach.

    Change from baseline in morning pre-dose trough FEV1 over 24 weeks. Primary endpoint, EU/SK/TW approach, Secondary endpoint US/China approach.

    Time frame: over 24 weeks

Secondary outcomes

  1. TDI Focal Score Over 24 Weeks, US/China and EU/SK/TW Approach

    TDI focal score over 24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9

    Time frame: over 24 Weeks

  2. TDI Focal Score Over Weeks 12-24 Japan Approach

    TDI focal score over 12-24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9

    Time frame: over Weeks 12-24

  3. TDI Focal Score Over 24 Weeks - US/China and EU/SK/TW Approaches -Symptomatic Population

    TDI focal score over 24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9

    Time frame: over 24 Weeks

  4. TDI Focal Score Over Weeks 12-24 - Japan Approach - Symptomatic Population

    TDI focal score over 12-24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9

    Time frame: over weeks 12-24

  5. Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing at Week 24 US/China Approach

    Peak change from baseline in FEV1 within 2 hours post-dosing at Week 24 US/China approach

    Time frame: at week 24

  6. Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over Weeks 12-24 Japan Approach

    Peak change from baseline in FEV1 within 2 hours post-dosing over weeks 12-24 Japan approach

    Time frame: over weeks 12-24

  7. Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks EU/SK/TW Approach

    Peak change from baseline in FEV1 within 2 hours post-dosing over 24 weeks EU/SK/TW approach

    Time frame: over 24 weeks

  8. Change From Baseline in SGRQ Total Score at Week 24, US/China Approach

    Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life

    Time frame: at week 24

  9. Change From Baseline in SGRQ Total Score Over Weeks 12-24 , Japan & EU/SK/TW Approach

    Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life

    Time frame: over weeks 12-24

  10. Change From Baseline in SGRQ Total Score at Week 24 in Symptomatic Population, US/China Approach

    Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life

    Time frame: at week 24

  11. Change From Baseline in SGRQ Total Score Over Weeks 12-24, in Symptomatic Population, Japan & EU/SK/TW Approach

    Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life

    Time frame: over weeks 12-24

  12. Change From Baseline in Average Daily Rescue Ventolin Use Over 24 Weeks in RVU Population, All Approaches

    Change from baseline in average daily rescue Ventolin use over 24 weeks in RVU population, all approaches

    Time frame: over 24 weeks

  13. FEV1 Measured at 5 Minutes Post-dose on Day 1

    Onset of Action as Assessed by FEV1 Day 1 at 5 Minutes Post-Dose. Reported is the FEV1 measured at 5 minutes post-dose on Day 1 as the first time point when the difference from Placebo was statistically significant

    Time frame: Assessed at 5-minutes post dose on Day 1

  14. FEV1 Measured at 15 Minutes Post-dose on Day 1

    Onset of Action as Assessed by FEV1 Day 1 at 15 Minutes Post-Dose. Reported is the FEV1 measured at 15 minutes post-dose on Day 1 as the first time point when the difference from Placebo was statistically significant

    Time frame: Assessed at 15-minute post dose on Day 1

07

Results

Posted Feb 20, 2019

Participant flow

The study was conducted at 175 sites in the United States, United Kingdom, Taiwan (TW),South Korea (SK), Russia, Poland, Hungary, Germany, Czech Republic, China, and Japan from April 2015 to August 2017. The entire study period was scheduled to take approximately 30 weeks for each individual subject from the time of screening.

Participant flow — Overall Study
MilestoneGFF MDI 14.4/9.6 ugFF MDI 9.6 ugGP MDI 14.4 ugPlacebo MDI
Started555483480238
Completed494417417200
Not completed61666338
Withdrew: Adverse event1514153
Withdrew: Lack of efficacy3848
Withdrew: Withdrawal by subject18172314
Withdrew: Physician decision1422
Withdrew: Lost to follow-up5531
Withdrew: Protocol violation2522
Withdrew: Protocol specified criteria1713148

Outcome measures

PrimaryChange From Baseline in Morning Pre-dose Trough FEV1 at Week 24 of Treatment (US/China Approach)

For the US/China approach, the primary endpoint was the change from baseline in morning pre-dose trough FEV1 at Week 24 of treatment

Time frame:
at week 24
Reported as:
Least squares mean · mL
Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 of Treatment (US/China Approach)
mLGFF MDI 14.4/9.6 ugFF MDI 9.6 ugGP MDI 14.4 ugPlacebo MDI
Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 of Treatment (US/China Approach)120 (102 to 138)47 (28 to 67)60 (41 to 80)-45 (-73 to -17)
PrimaryChange From Baseline in Morning Pre-dose Trough FEV1 Over Weeks 12-24, Japan Approach

Change from baseline in morning pre-dose trough FEV1 over weeks 12-24, Japan approach

Time frame:
over weeks 12-24
Reported as:
Least squares mean · mL
Change From Baseline in Morning Pre-dose Trough FEV1 Over Weeks 12-24, Japan Approach
mLGFF MDI 14.4/9.6 ugFF MDI 9.6 ugGP MDI 14.4 ugPlacebo MDI
Change From Baseline in Morning Pre-dose Trough FEV1 Over Weeks 12-24, Japan Approach128 (113 to 143)54 (38 to 71)74 (58 to 91)-25 (-49 to -1)
PrimaryChange From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks. Primary Endpoint, EU/SK/TW Approach, Secondary Endpoint US/China Approach.

Change from baseline in morning pre-dose trough FEV1 over 24 weeks. Primary endpoint, EU/SK/TW approach, Secondary endpoint US/China approach.

Time frame:
over 24 weeks
Reported as:
Least squares mean · mL
Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks. Primary Endpoint, EU/SK/TW Approach, Secondary Endpoint US/China Approach.
mLGFF MDI 14.4/9.6 ugFF MDI 9.6 ugGP MDI 14.4 ugPlacebo MDI
Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks. Primary Endpoint, EU/SK/TW Approach, Secondary Endpoint US/China Approach.135 (121 to 149)63 (48 to 78)80 (65 to 94)-20 (-41 to 2)
SecondaryTDI Focal Score Over 24 Weeks, US/China and EU/SK/TW Approach

TDI focal score over 24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9

Time frame:
over 24 Weeks
Reported as:
Least squares mean · Scores on a scale
TDI Focal Score Over 24 Weeks, US/China and EU/SK/TW Approach
Scores on a scaleGFF MDI 14.4/9.6 ugFF MDI 9.6 ugGP MDI 14.4 ugPlacebo MDI
TDI Focal Score Over 24 Weeks, US/China and EU/SK/TW Approach1.6 (1.4 to 1.8)1.5 (1.3 to 1.7)1.3 (1.1 to 1.5)0.8 (0.5 to 1.1)
SecondaryTDI Focal Score Over Weeks 12-24 Japan Approach

TDI focal score over 12-24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9

Time frame:
over Weeks 12-24
Reported as:
Least squares mean · Scores on a scale
TDI Focal Score Over Weeks 12-24 Japan Approach
Scores on a scaleGFF MDI 14.4/9.6 ugFF MDI 9.6 ugGP MDI 14.4 ugPlacebo MDI
TDI Focal Score Over Weeks 12-24 Japan Approach1.7 (1.5 to 1.9)1.5 (1.3 to 1.7)1.4 (1.2 to 1.6)0.8 (0.5 to 1.1)
SecondaryTDI Focal Score Over 24 Weeks - US/China and EU/SK/TW Approaches -Symptomatic Population

TDI focal score over 24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9

Time frame:
over 24 Weeks
Reported as:
Least squares mean · Scores on a scale
TDI Focal Score Over 24 Weeks - US/China and EU/SK/TW Approaches -Symptomatic Population
Scores on a scaleGFF MDI 14.4/9.6 ugFF MDI 9.6 ugGP MDI 14.4 ugPlacebo MDI
TDI Focal Score Over 24 Weeks - US/China and EU/SK/TW Approaches -Symptomatic Population1.5 (1.2 to 1.7)1.3 (1.0 to 1.6)1.1 (0.8 to 1.3)0.7 (0.3 to 1.2)
SecondaryTDI Focal Score Over Weeks 12-24 - Japan Approach - Symptomatic Population

TDI focal score over 12-24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9

Time frame:
over weeks 12-24
Reported as:
Least squares mean · Scores on a scale
TDI Focal Score Over Weeks 12-24 - Japan Approach - Symptomatic Population
Scores on a scaleGFF MDI 14.4/9.6 ugFF MDI 9.6 ugGP MDI 14.4 ugPlacebo MDI
TDI Focal Score Over Weeks 12-24 - Japan Approach - Symptomatic Population1.5 (1.2 to 1.8)1.4 (1.0 to 1.7)1.1 (0.8 to 1.4)0.7 (0.2 to 1.2)
SecondaryPeak Change From Baseline in FEV1 Within 2 Hours Post-dosing at Week 24 US/China Approach

Peak change from baseline in FEV1 within 2 hours post-dosing at Week 24 US/China approach

Time frame:
at week 24
Reported as:
Least squares mean · mL
Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing at Week 24 US/China Approach
mLGFF MDI 14.4/9.6 ugFF MDI 9.6 ugGP MDI 14.4 ugPlacebo MDI
Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing at Week 24 US/China Approach358 (338 to 378)247 (226 to 269)214 (192 to 235)55 (24 to 87)
SecondaryPeak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over Weeks 12-24 Japan Approach

Peak change from baseline in FEV1 within 2 hours post-dosing over weeks 12-24 Japan approach

Time frame:
over weeks 12-24
Reported as:
Least squares mean · mL
Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over Weeks 12-24 Japan Approach
mLGFF MDI 14.4/9.6 ugFF MDI 9.6 ugGP MDI 14.4 ugPlacebo MDI
Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over Weeks 12-24 Japan Approach368 (350 to 386)255 (236 to 274)228 (209 to 248)70 (42 to 98)
SecondaryPeak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks EU/SK/TW Approach

Peak change from baseline in FEV1 within 2 hours post-dosing over 24 weeks EU/SK/TW approach

Time frame:
over 24 weeks
Reported as:
Least squares mean · mL
Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks EU/SK/TW Approach
mLGFF MDI 14.4/9.6 ugFF MDI 9.6 ugGP MDI 14.4 ugPlacebo MDI
Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks EU/SK/TW Approach375 (360 to 389)277 (261 to 293)234 (218 to 250)82 (58 to 105)
SecondaryChange From Baseline in SGRQ Total Score at Week 24, US/China Approach

Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life

Time frame:
at week 24
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in SGRQ Total Score at Week 24, US/China Approach
Scores on a scaleGFF MDI 14.4/9.6 ugFF MDI 9.6 ugGP MDI 14.4 ugPlacebo MDI
Change From Baseline in SGRQ Total Score at Week 24, US/China Approach-5.3 (-6.4 to -4.2)-5.6 (-6.8 to -4.4)-3.7 (-4.8 to -2.5)-0.9 (-2.6 to 0.8)
SecondaryChange From Baseline in SGRQ Total Score Over Weeks 12-24 , Japan & EU/SK/TW Approach

Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life

Time frame:
over weeks 12-24
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in SGRQ Total Score Over Weeks 12-24 , Japan & EU/SK/TW Approach
Scores on a scaleGFF MDI 14.4/9.6 ugFF MDI 9.6 ugGP MDI 14.4 ugPlacebo MDI
Change From Baseline in SGRQ Total Score Over Weeks 12-24 , Japan & EU/SK/TW Approach-5.2 (-6.1 to -4.3)-5.0 (-5.9 to -4.0)-3.6 (-4.6 to -2.6)-1.7 (-3.1 to -0.3)
SecondaryChange From Baseline in SGRQ Total Score at Week 24 in Symptomatic Population, US/China Approach

Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life

Time frame:
at week 24
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in SGRQ Total Score at Week 24 in Symptomatic Population, US/China Approach
Scores on a scaleGFF MDI 14.4/9.6 ugFF MDI 9.6 ugGP MDI 14.4 ugPlacebo MDI
Change From Baseline in SGRQ Total Score at Week 24 in Symptomatic Population, US/China Approach-6.9 (-8.6 to -5.2)-7.8 (-9.7 to -5.9)-3.8 (-5.6 to -2.0)-1.6 (-4.3 to 1.1)
SecondaryChange From Baseline in SGRQ Total Score Over Weeks 12-24, in Symptomatic Population, Japan & EU/SK/TW Approach

Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life

Time frame:
over weeks 12-24
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in SGRQ Total Score Over Weeks 12-24, in Symptomatic Population, Japan & EU/SK/TW Approach
Scores on a scaleGFF MDI 14.4/9.6 ugFF MDI 9.6 ugGP MDI 14.4 ugPlacebo MDI
Change From Baseline in SGRQ Total Score Over Weeks 12-24, in Symptomatic Population, Japan & EU/SK/TW Approach-6.9 (-8.4 to -5.4)-7.3 (-8.9 to -5.6)-3.9 (-5.5 to -2.4)-3.1 (-5.4 to -0.8)
SecondaryChange From Baseline in Average Daily Rescue Ventolin Use Over 24 Weeks in RVU Population, All Approaches

Change from baseline in average daily rescue Ventolin use over 24 weeks in RVU population, all approaches

Time frame:
over 24 weeks
Reported as:
Least squares mean · Puffs/day
Change From Baseline in Average Daily Rescue Ventolin Use Over 24 Weeks in RVU Population, All Approaches
Puffs/dayGFF MDI 14.4/9.6 ugFF MDI 9.6 ugGP MDI 14.4 ugPlacebo MDI
Change From Baseline in Average Daily Rescue Ventolin Use Over 24 Weeks in RVU Population, All Approaches-1.4 (-1.7 to -1.1)-1.0 (-1.3 to -0.7)-0.6 (-0.9 to -0.3)-0.4 (-0.8 to -0.0)
SecondaryFEV1 Measured at 5 Minutes Post-dose on Day 1

Onset of Action as Assessed by FEV1 Day 1 at 5 Minutes Post-Dose. Reported is the FEV1 measured at 5 minutes post-dose on Day 1 as the first time point when the difference from Placebo was statistically significant

Time frame:
Assessed at 5-minutes post dose on Day 1
Reported as:
Least squares mean · Liters
FEV1 Measured at 5 Minutes Post-dose on Day 1
LitersGFF MDI 14.4/9.6 ugFF MDI 9.6 ugGP MDI 14.4 ugPlacebo MDI
FEV1 Measured at 5 Minutes Post-dose on Day 10.202 (0.191 to 0.212)0.186 (0.175 to 0.197)0.059 (0.048 to 0.070)0.022 (0.006 to 0.038)
SecondaryFEV1 Measured at 15 Minutes Post-dose on Day 1

Onset of Action as Assessed by FEV1 Day 1 at 15 Minutes Post-Dose. Reported is the FEV1 measured at 15 minutes post-dose on Day 1 as the first time point when the difference from Placebo was statistically significant

Time frame:
Assessed at 15-minute post dose on Day 1
Reported as:
Least squares mean · Liters
FEV1 Measured at 15 Minutes Post-dose on Day 1
LitersGFF MDI 14.4/9.6 ugFF MDI 9.6 ugGP MDI 14.4 ugPlacebo MDI
FEV1 Measured at 15 Minutes Post-dose on Day 10.241 (0.230 to 0.252)0.220 (0.208 to 0.231)0.105 (0.093 to 0.117)0.033 (0.016 to 0.050)

Adverse events

Collected over Adverse events were collected from the time the subject signed consent throughout the four treatment periods of 24 weeks and up to 10 days following the last dose of study drug.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GFF MDI 14.4/9.6 ug1/551 (0.2%)53/551 (9.6%)166/551 (30.1%)
FF MDI 9.6 ug1/480 (0.2%)40/480 (8.3%)123/480 (25.6%)
GP MDI 14.4 ug1/474 (0.2%)34/474 (7.2%)128/474 (27%)
Placebo MDI1/235 (0.4%)19/235 (8.1%)61/235 (26%)
Most frequent serious events
Showing 10 of 97
Most frequent serious events
EventGFF MDI 14.4/9.6 ugFF MDI 9.6 ugGP MDI 14.4 ugPlacebo MDI
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders16/55113/48012/4747/235
PneumoniaInfections and infestations7/5512/4803/4743/235
CellulitisInfections and infestations3/5510/4800/4740/235
PneumothoraxRespiratory, thoracic and mediastinal disorders0/5510/4801/4741/235
Gastrointestinal InfectionInfections and infestations0/5510/4800/4741/235
Gastrointestinal haemorrhageGastrointestinal disorders1/5510/4800/4741/235
Lung cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/5510/4800/4741/235
Cardiac myxomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/5510/4800/4741/235
Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/5510/4800/4741/235
Rib fractureInjury, poisoning and procedural complications1/5510/4800/4741/235
Most frequent other events
Most frequent other events
EventGFF MDI 14.4/9.6 ugFF MDI 9.6 ugGP MDI 14.4 ugPlacebo MDI
Viral upper respiratory tract infectionInfections and infestations50/55146/48044/47416/235
Upper respiratory tract infectionInfections and infestations37/55129/48033/47420/235
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders16/55113/48012/4747/235
DyspnoeaRespiratory, thoracic and mediastinal disorders11/5517/4806/4747/235
Back PainMusculoskeletal and connective tissue disorders15/5515/4807/4741/235
PneumoniaInfections and infestations9/5515/4805/4746/235
CoughRespiratory, thoracic and mediastinal disorders13/5518/48010/4742/235
BronchitisInfections and infestations4/5516/4808/4745/235
PharyngitisInfections and infestations11/5514/4803/4740/235

Baseline characteristics

The data reported from one site was not included in the final analysis.

Age, Continuous
Age, Continuous(Years)GFF MDI 14.4/9.6 ugFF MDI 9.6 ugGP MDI 14.4 ugPlacebo MDITotal
Mean64.7 ± 7.464.1 ± 7.664.0 ± 8.163.9 ± 7.564.2 ± 7.7
Sex: Female, Male
Sex: Female, Male(Participants)GFF MDI 14.4/9.6 ugFF MDI 9.6 ugGP MDI 14.4 ugPlacebo MDITotal
Female14311512864450
Male4083653461711290
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GFF MDI 14.4/9.6 ugFF MDI 9.6 ugGP MDI 14.4 ugPlacebo MDITotal
American Indian or Alaska Native10001
Asian22320418192700
Native Hawaiian or Other Pacific Islander00000
Black or African American121618652
White315260275137987
More than one race00000
Unknown or Not Reported00000
08

Study locations

167 sites
  • Research Site
    Andalusia, Alabama 36420, United States
  • Research Site
    Birmingham, Alabama 35209, United States
  • Research Site
    Foley, Alabama 36535, United States
  • Research Site
    Jasper, Alabama 35501, United States
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    Boulder, Colorado 80301, United States
  • Research Site
    Clearwater, Florida 33756, United States
  • Research Site
    Clearwater, Florida 33765, United States
  • Research Site
    Kissimmee, Florida 34744, United States
  • Research Site
    Miami, Florida 33175, United States
  • Research Site
    Miami, Florida 33186, United States
  • Research Site
    Panama City, Florida 32405, United States
  • Research Site
    Pensacola, Florida 32503, United States
  • Research Site
    Tamarac, Florida 33321, United States
  • Research Site
    Tampa, Florida 33603, United States
  • Research Site
    Winter Park, Florida 32789-4681, United States
  • Research Site
    Atlanta, Georgia 30331, United States
  • Research Site
    Blue Ridge, Georgia 30513, United States
  • Research Site
    North Dartmouth, Massachusetts 02747, United States
  • Research Site
    Edina, Minnesota 55435, United States
  • Research Site
    Fridley, Minnesota 55432, United States
  • Research Site
    Minneapolis, Minnesota 55407, United States
  • Research Site
    Woodbury, Minnesota 55125, United States
  • Research Site
    Saint Charles, Missouri 63301, United States
  • Research Site
    Saint Louis, Missouri 63141, United States
  • Research Site
    Gastonia, North Carolina 28054, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Cincinnati, Ohio 45242, United States
  • Research Site
    Columbus, Ohio 43215, United States
  • Research Site
    Columbus, Ohio 43231, United States
  • Research Site
    Dayton, Ohio 45419, United States
  • Research Site
    Dayton, Ohio 45459, United States
  • Research Site
    Dublin, Ohio 43016, United States
  • Research Site
    Oklahoma City, Oklahoma 73103, United States
  • Research Site
    Medford, Oregon 97504, United States
  • Research Site
    Easley, South Carolina 29640, United States
  • Research Site
    Gaffney, South Carolina 29341, United States
  • Research Site
    Greenville, South Carolina 29615, United States
  • Research Site
    Rock Hill, South Carolina 29732, United States
  • Research Site
    Seneca, South Carolina 29678, United States
  • Research Site
    Spartanburg, South Carolina 29303, United States
  • Research Site
    Union, South Carolina 29379, United States
  • Research Site
    Johnson City, Tennessee 37601, United States
  • Research Site
    Abingdon, Virginia 24210, United States
  • Research Site
    Beijing, 100029, China
  • Research Site
    Beijing, 100050, China
  • Research Site
    Beijing, 100144, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410011, China
  • Research Site
    Chengdu, 610083, China
  • Research Site
    Chengdu, CN-610041, China
  • Research Site
    Guangzhou, 510000, China
  • Research Site
    Guangzhou, 510120, China
  • Research Site
    Guangzhou, 510515, China
  • Research Site
    Guiyang, 510630, China
  • Research Site
    Haikou, 570311, China
  • Research Site
    Hefei, 230001, China
  • Research Site
    Hohhot, 010017, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Nanning, 530021, China
  • Research Site
    Shanghai, 200040, China
  • Research Site
    Shanghai, 200120, China
  • Research Site
    Shanghai, 200433, China
  • Research Site
    Shengyang, 110004, China
  • Research Site
    Shenyang, 110016, China
  • Research Site
    Shijiazhuang, 050000, China
  • Research Site
    Shijiazhuang, 050051, China
  • Research Site
    Soochow City, 215006, China
  • Research Site
    Taiyuan, 030001, China
  • Research Site
    Tianjin, 300052, China
  • Research Site
    Wuxi, 214023, China
  • Research Site
    Xiamen, 361004, China
  • Research Site
    Xining, 810007, China
  • Research Site
    Yiyang Shi, 413000, China
  • Research Site
    Jindrichuv Hradec, 37701, Czechia
  • Research Site
    Ostrava-Hrabuvka, 700 30, Czechia
  • Research Site
    Praha, 15000, Czechia
  • Research Site
    Teplice, 415 01, Czechia
  • Research Site
    Augsburg, 86150, Germany
  • Research Site
    Berlin, 10629, Germany
  • Research Site
    Berlin, 10787, Germany
  • Research Site
    Berlin, 12157, Germany
  • Research Site
    Grosshansdof, 22927, Germany
  • Research Site
    Hamburg, 20354, Germany
  • Research Site
    Leipzig, 04103, Germany
  • Research Site
    Leipzig, 04357, Germany
  • Research Site
    Lübeck, 23552, Germany
  • Research Site
    Wiesbaden, 65187, Germany
  • Research Site
    Budapest, 1135, Hungary
  • Research Site
    Gödöllő, 2100, Hungary
  • Research Site
    Nyíregyháza, 4400, Hungary
  • Research Site
    Pécs, 7635, Hungary
  • Research Site
    Siófok, 8600, Hungary
  • Research Site
    Szeged, H-6722, Hungary
  • Research Site
    Ako-shi, 678-0239, Japan
  • Research Site
    Asahikawa-shi, 070-8644, Japan
  • Research Site
    Chuo-ku, 103-0027, Japan
  • Research Site
    Chuo-ku, 103-0028, Japan
  • Research Site
    Fukuoka-shi, 811-1394, Japan

Showing the first 100 of 167 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Singh D, Hurst JR, Martinez FJ, Rabe KF, Bafadhel M, Jenkins M, Salazar D, Dorinsky P, Darken P. Predictive modeling of COPD exacerbation rates using baseline risk factors. Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221107314. doi: 10.1177/17534666221107314. PubMed 35815359 ↗
  • Martinez FJ, Lipworth BJ, Rabe KF, Collier DJ, Ferguson GT, Sethi S, Feldman GJ, O'Brien G, Jenkins M, Reisner C. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies. Respir Res. 2020 May 25;21(1):128. doi: 10.1186/s12931-020-01388-y. PubMed 32450869 ↗
  • Martinez FJ, Rabe KF, Lipworth BJ, Arora S, Jenkins M, Martin UJ, Reisner C. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies. Int J Chron Obstruct Pulmon Dis. 2020 Jan 9;15:99-106. doi: 10.2147/COPD.S229794. eCollection 2020. PubMed 32021148 ↗
  • Chen R, Zhong N, Wang HY, Zhao L, Mei X, Qin Z, Huang J, Assam PN, Maes A, Siddiqui S, Martin UJ, Reisner C. Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD. Int J Chron Obstruct Pulmon Dis. 2020 Jan 8;15:43-56. doi: 10.2147/COPD.S223638. eCollection 2020. PubMed 32021143 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AstraZeneca's policy is to share data with researchers if the request is in scope of our policy. The policy and additional information can be found on astrazenecaclinicaltrials.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Aug 2017, 29 months.

Results were first posted in Feb 2019, 1 year 5 months after primary completion.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 29 months is above that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2015
First posted
Jan 22, 2015
StartActual
Mar 30, 2015
Primary completionActual
Aug 31, 2017
CompletionActual
Aug 31, 2017
Results first posted
Feb 20, 2019
Last update
Feb 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02343458
Responsible party
Sponsor
First posted
Jan 22, 2015
Start date
Mar 30, 2015
Primary completion
Aug 31, 2017
Completion
Aug 31, 2017
Results posted
Feb 20, 2019
Last update
Feb 20, 2019

Study contacts

Colin Reisner, MD
study chair · Pearl Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glycopyrrolate · Formoterol

Start the discussion